CD82 Antibody - middle region
Rabbit Polyclonal Antibody
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application ![]()
| WB |
---|---|
Primary Accession | P27701 |
Other Accession | NM_001024844, NP_001020015 |
Reactivity | Human |
Predicted | Human |
Host | Rabbit |
Clonality | Polyclonal |
Calculated MW | 27kDa |
Gene ID | 3732 |
---|---|
Alias Symbol | 4F9, C33, GR15, IA4, KAI1, R2, SAR2, ST6, TSPAN27 |
Other Names | CD82 antigen, C33 antigen, IA4, Inducible membrane protein R2, Metastasis suppressor Kangai-1, Suppressor of tumorigenicity 6 protein, Tetraspanin-27, Tspan-27, CD82, CD82, KAI1, SAR2, ST6, TSPAN27 |
Format | Liquid. Purified antibody supplied in 1x PBS buffer with 0.09% (w/v) sodium azide and 2% sucrose. |
Reconstitution & Storage | Add 50 ul of distilled water. Final anti-CD82 antibody concentration is 1 mg/ml in PBS buffer with 2% sucrose. For longer periods of storage, store at 20°C. Avoid repeat freeze-thaw cycles. |
Precautions | CD82 Antibody - middle region is for research use only and not for use in diagnostic or therapeutic procedures. |
Name | CD82 |
---|---|
Synonyms | KAI1, SAR2, ST6, TSPAN27 |
Function | Structural component of specialized membrane microdomains known as tetraspanin-enriched microdomains (TERMs), which act as platforms for receptor clustering and signaling (PubMed:19497983). Participates thereby in diverse biological functions such as cell signal transduction, adhesion, migration and protein trafficking. Acts as a attenuator of EGF signaling, facilitating ligand-induced endocytosis of the receptor and its subsequent desensitization (PubMed:10985391, PubMed:35538033). Mechanistically, modulates ligand- induced ubiquitination and trafficking of EGFR via E3 ligase CBL phosphorylation by PKC (PubMed:23897813). Increases cell-matrix adhesion by regulating the membrane organization of integrin alpha4/ITA4 (PubMed:24623721, PubMed:8757325). Modulates adhesion and suppresses cell migration through other integrins such as the alpha6/ITGA6 and beta1/ITGB1 (PubMed:15557282, PubMed:17560548). Decreases cell-associated plasminogen activation by interfering with the interaction between urokinase-type plasminogen activator/PLAU and its receptor PLAUR (PubMed:15677461). Associates with CD4 or CD8 and delivers costimulatory signals for the TCR/CD3 pathway. Plays a role in TLR9 trafficking to acidified CpG-containing compartments by controlling interaction between TLR9 and VAMP3 and subsequent myddosome assembly (By similarity). Inhibits LPS-induced inflammatory response by preventing binding of LPS to TLR4 on the cell surface (PubMed:36945827). Plays a role in the activation of macrophages into anti-inflammatory phenotypes (By similarity). Independently of Toll- like receptor (TLR) signaling, is recruited to pathogen-containing phagosomes prior to fusion with lysosomes and thereby participates in antigen presentation (By similarity). Acts also to control angiogenesis and switch angiogenic milieu to quiescent state by binding and sequestering VEGFA and PDGFB to inhibit the signaling they trigger via their respective cell surface receptor (PubMed:34530889). |
Cellular Location | Cell membrane {ECO:0000269|PubMed:19497983, ECO:0000269|PubMed:23897813, ECO:0000269|PubMed:30463011, ECO:0000269|PubMed:34530889, ECO:0000269|PubMed:8757325, ECO:0000269|Ref.4}; Multi-pass membrane protein Cytoplasmic vesicle, phagosome {ECO:0000250|UniProtKB:P40237} |
Tissue Location | Lymphoid specific. |

Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
References
Gaugitsch H.W.,et al.Eur. J. Immunol. 21:377-383(1991).
Imai T.,et al.J. Immunol. 149:2879-2886(1992).
Dong J.T.,et al.Science 268:884-886(1995).
Zhou G.,et al.Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
Dong J.T.,et al.Genomics 41:25-32(1997).

If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.